Literature DB >> 22521913

Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens.

Sampa Santra1, Mark Muldoon, Sydeaka Watson, Adam Buzby, Harikrishnan Balachandran, Kevin R Carlson, Linh Mach, Wing-Pui Kong, Krisha McKee, Zhi-Yong Yang, Srinivas S Rao, John R Mascola, Gary J Nabel, Bette T Korber, Norman L Letvin.   

Abstract

To create an HIV-1 vaccine that generates sufficient breadth of immune recognition to protect against the genetically diverse forms of the circulating virus, we have been exploring vaccines based on consensus and mosaic protein designs. Increasing the valency of a mosaic immunogen cocktail increases epitope coverage but with diminishing returns, as increasingly rare epitopes are incorporated into the mosaic proteins. In this study we compared the immunogenicity of 2-valent and 3-valent HIV-1 envelope mosaic immunogens in rhesus monkeys. Immunizations with the 3-valent mosaic immunogens resulted in a modest increase in the breadth of vaccine-elicited T lymphocyte responses compared to the 2-valent mosaic immunogens. However, the 3-valent mosaic immunogens elicited significantly higher neutralizing responses to Tier 1 viruses than the 2-valent mosaic immunogens. These findings underscore the potential utility of polyvalent mosaic immunogens for eliciting both cellular and humoral immune responses to HIV-1.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521913      PMCID: PMC3582221          DOI: 10.1016/j.virol.2012.03.012

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  30 in total

1.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.

Authors:  Sampa Santra; Michael S Seaman; Ling Xu; Dan H Barouch; Carol I Lord; Michelle A Lifton; Darci A Gorgone; Kristin R Beaudry; Krisha Svehla; Brent Welcher; Bimal K Chakrabarti; Yue Huang; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

Authors:  Will Fischer; Simon Perkins; James Theiler; Tanmoy Bhattacharya; Karina Yusim; Robert Funkhouser; Carla Kuiken; Barton Haynes; Norman L Letvin; Bruce D Walker; Beatrice H Hahn; Bette T Korber
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

6.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

7.  A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates.

Authors:  Dan H Barouch; Zhi-yong Yang; Wing-pui Kong; Birgit Korioth-Schmitz; Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Ayako Miura; John R Mascola; Norman L Letvin; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.

Authors:  Y Huang; W P Kong ; G J Nabel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

10.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

View more
  32 in total

1.  Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys.

Authors:  Kathryn E Stephenson; Adam SanMiguel; Nathaniel L Simmons; Kaitlin Smith; Mark G Lewis; James J Szinger; Bette Korber; Dan H Barouch
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 2.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

3.  Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Christine A Bricault; Ann Cheung; Jennifer Shields; James Perry; James M Kovacs; Elena Giorgi; Margot van Winsen; Adrian Apetri; Els C M Brinkman-van der Linden; Bing Chen; Bette Korber; Michael S Seaman; Dan H Barouch
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

4.  Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages.

Authors:  Will Fischer; Cristian Apetrei; Mario L Santiago; Yingying Li; Rajeev Gautam; Ivona Pandrea; George M Shaw; Beatrice H Hahn; Norman L Letvin; Gary J Nabel; Bette T Korber
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

5.  Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.

Authors:  Sandrine L Hulot; Bette Korber; Elena E Giorgi; Nathan Vandergrift; Kevin O Saunders; Harikrishnan Balachandran; Linh V Mach; Michelle A Lifton; Giuseppe Pantaleo; Jim Tartaglia; Sanjay Phogat; Bertram Jacobs; Karen Kibler; Beatriz Perdiguero; Carmen E Gomez; Mariano Esteban; Margherita Rosati; Barbara K Felber; George N Pavlakis; Robert Parks; Krissey Lloyd; Laura Sutherland; Richard Scearce; Norman L Letvin; Michael S Seaman; S Munir Alam; David Montefiori; Hua-Xin Liao; Barton F Haynes; Sampa Santra
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

6.  Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.

Authors:  Patricio Oyarzún; Bostjan Kobe
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

7.  Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains.

Authors:  Karina Yusim; Rebecca Dilan; Erica Borducchi; Kelly Stanley; Elena Giorgi; William Fischer; James Theiler; Joseph Marcotrigiano; Bette Korber; Dan H Barouch
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

Review 8.  Vaccine design: emerging concepts and renewed optimism.

Authors:  Sebastian K Grimm; Margaret E Ackerman
Journal:  Curr Opin Biotechnol       Date:  2013-03-07       Impact factor: 9.740

9.  Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.

Authors:  Anju Bansal; Tiffanie Mann; Sarah Sterrett; Binghao J Peng; Anne Bet; Jonathan M Carlson; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2015-09-01       Impact factor: 3.731

10.  Graph-theoretical formulation of the generalized epitope-based vaccine design problem.

Authors:  Emilio Dorigatti; Benjamin Schubert
Journal:  PLoS Comput Biol       Date:  2020-10-23       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.